about
Hereditary early-onset Parkinson's disease caused by mutations in PINK1Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36Dystonia and Tremor: The Clinical Syndromes with Isolated TremorThe diverse phenotype and genotype of pantothenate kinase-associated neurodegenerationClinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegenerationA comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissureAttentional networks in Parkinson's disease.Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants.A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force.Apomorphine and levodopa challenge in patients with a focal midbrain lesion.Consensus statement on the diagnosis of multiple system atrophy.Obsessive-compulsive behaviour and cognitive impairment in a parkinsonian patient after left putaminal lesion.Botulinum toxin in motor disorders.Primary focal hyperhidrosis in a new family not linked to known loci.Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study.Disability and profiles of functioning of patients with Parkinson's disease described with ICF classification.PARK6 is a common cause of familial parkinsonism.Phenomenology and classification of dystonia: a consensus update.PINK1 mutations are associated with sporadic early-onset parkinsonism.Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment.The New Classification System for the Dystonias: Why Was it Needed and How was it Developed?Dystonia in parkinsonian syndromes.Review: several drugs are efficacious for symptomatic treatment of Parkinson disease.Diagnostic criteria for Parkinson's disease.Surgery of Parkinson's disease: inclusion criteria and follow-up.Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study groupCognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease.Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystoniaTreatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms.Levodopa in the treatment of Parkinson's disease: current controversies.Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature.Safety and efficacy of botulinum toxin type A following long-term use.Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteriaResults by motor cortex stimulation in treatment of focal dystonia, Parkinson's disease and post-ictal spasticity. The experience of the Italian Study Group of the Italian Neurosurgical Society.Rivastigmine in Parkinson's disease dementia.Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosisLevodopa-induced dyskinesias and their management.A genome-wide association study in multiple system atrophy.
P50
Q24337084-8DB7B8B7-C663-4C94-8C85-490603311F4AQ24536382-F3898682-0EB5-4778-90BB-68D175EC1B95Q26751639-423A73A2-98F6-4C4E-82C8-E6C92EE46725Q28252508-317B347F-7910-4B40-B0E4-ABC670FA998AQ28284102-ECEEB0B2-9B45-4980-9992-15F2FC4F3D7BQ28368673-62438944-D3E3-4B61-BDD0-5345822CD271Q30360449-4D67BDF7-9D3B-4188-A542-277DA00E31F5Q33159140-18854E2C-9FEB-40D5-8AC6-4C5D3B15341FQ33244571-B4D7BB17-D2C3-4EF1-8DAE-C5A9637D3928Q33544928-E3B8ECE0-2DEA-41D7-B776-58E21FC6C723Q33605440-4A8BAB6D-BD00-42E1-A8C4-0C5EE5E84D31Q33715012-4D7E7568-DDD9-496B-9EA6-4F29FCA1E015Q33771319-3863F3E3-392F-446C-BFB5-4A8310D79DFDQ34124524-A053E341-41EF-40D0-BAB2-71CFC97086B0Q34160601-870A1C17-FE13-45E4-8070-7098E20993B4Q34172627-9B2530FD-7940-4141-A334-7EC85F8929C9Q34172948-BAE8BF47-086C-4F89-BA41-BECF71996728Q34343247-9BF99035-BCFF-40A8-85A9-1D98BFAE43D6Q34345883-E8D81C12-365A-4A20-AC75-0C98F155E4F1Q34376919-7AA28E70-D0AD-4D50-B8C5-93EF30A6CC5CQ34574023-B18BA26C-9CD2-452A-A4FD-82DE3563EAE6Q34626729-6B6BA832-10F1-43C8-9ECD-BD27DB781BE3Q35004839-51D45D3E-20BF-43D4-8277-9AAFE396B9A4Q35038094-06FA00D0-8464-4F6C-AFB1-C7F28A70BE52Q35139934-7CF20ABF-F781-4D78-B82E-5FB2884CA497Q35139946-A3564FE3-4A58-46D5-A793-02F484EF4D94Q35453838-33E3EB5D-C865-4E26-9205-6DB037C85C1DQ35471433-7236095B-0EAD-4671-9857-1444B4CFC846Q35473508-3C8966BF-8F7A-4025-8AFA-6BCECF802746Q35694013-FC2AE0B2-6E2B-47D6-BC8D-E8EDF102E8CEQ35889917-97CD969A-EA36-4269-857A-732D509C5F35Q36171693-1E6D88B2-9011-4D67-B36B-AD6D75103585Q36506439-DEB37D2B-F9E5-4315-AC7B-DAB7D936C995Q36656478-09870F9B-A680-4272-A4FD-4BFC8636D3FCQ36879516-8B5FAFEF-E752-48B5-994B-8F5DA8D72B4AQ37222511-C0FA9539-73A4-46E6-B7FB-A1B6D42ACAD2Q37232006-0376C918-8185-4C67-89FB-1AABA4B9DF93Q37257418-CBFC183C-8873-465F-9B17-50E4E1C56A85Q37280804-449790EF-9821-4C92-845F-0AD14F083942Q37345458-65391204-A557-4840-99D5-E6EA9D597C3A
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Alberto Albanese
@ast
Alberto Albanese
@de
Alberto Albanese
@en
Alberto Albanese
@es
Alberto Albanese
@fr
Alberto Albanese
@nl
Alberto Albanese
@sl
type
label
Alberto Albanese
@ast
Alberto Albanese
@de
Alberto Albanese
@en
Alberto Albanese
@es
Alberto Albanese
@fr
Alberto Albanese
@nl
Alberto Albanese
@sl
altLabel
A Albanese
@en
prefLabel
Alberto Albanese
@ast
Alberto Albanese
@de
Alberto Albanese
@en
Alberto Albanese
@es
Alberto Albanese
@fr
Alberto Albanese
@nl
Alberto Albanese
@sl
P950
P1053
K-7396-2016
P106
P1153
7101798303
P21
P214
7148703907636930817
P31
P3762
P4012
P496
0000-0002-5864-0006
P734
P735
P7859
viaf-7148703907636930817